Fr532 THE EFFECT OF GUSELKUMAB INDUCTION THERAPY ON INFLAMMATORY BIOMARKERS IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE: WEEK 12 RESULTS FROM THE PHASE 2 GALAXI 1 STUDY
Bruce E. Sands(Icahn School of Medicine at Mount Sinai), William J. Sandborn(University of San Diego), Zijiang Yang(Henan Medical University), Anita Afzali, Louis R. Ghanem(Johnson & Johnson (United States)), Daphne Chan(Janssen (United States)), Jane M. Andrews(Health Net), Silvio Danese(IRCCS Ospedale San Raffaele), Melissa Cunningham(Medical University of South Carolina), Kathleen Weisel, Remo Panaccione(University of Calgary), Jewel Johanns(Johnson & Johnson (United States)), Mary Ellen Frustaci(Johnson & Johnson (United States))
Cited by 5
Related Papers
Host–microbe interactions have shaped the genetic architecture of inflammatory bowel disease
|Nature|2012|4.8k
Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2005|3.9k
Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2013|2.9k
Dysfunction of the intestinal microbiome in inflammatory bowel disease and treatment
|Genome biology|2012|2.8k
Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease
|New England Journal of Medicine|2013|2.7k